Moving in Rhythm

When Ipsen Group (Euronext:IPN) made a strategic decision that metabolic indications were no longer a core focus, MPM Capital and New Enterprise Associates were ready to pick up some of its preclinical programs, NEA's Ed Mathers told Ebb & Flow.

The result is Rhythm Pharmaceuticals Inc., which last week disclosed a $21 million series A round to finance the in-licensing earlier this month of ghrelin agonists and melanocyte-stimulating hormone agonists from Ipsen...